newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center

  • IGC Pharma expanded its Phase 2 CALMA trial for IGC-AD1 into Colombia by adding the Grupo de Neurociencias de Antioquia (GNA) site.
  • The GNA addition broadens genetic diversity & strengthens the path toward the 2026 data catalyst for the lead asset.
  • The clinical network now includes 23 active sites across 26 locations in the US & Canada.
  • The CALMA trial is a randomized, double-blind, placebo-controlled study that has reached approximately 70% of planned enrollment.
  • IGC expects to complete enrollment by mid-2026, which is a primary operational gating step before database lock & top-line results.
  • Dr. Claudia Ramos serves as Principal Investigator at the Colombia site, leading a multidisciplinary team alongside Dr. David Aguillón.
  • GNA is recognized for long-running research into genetically linked Alzheimer's disease, including longitudinal cohorts & biomarker research.
  • IGC honored the legacy of Dr. Francisco Lopera, the founder of GNA who passed away in September 2024.
  • IGC Pharma is a clinical-stage biotechnology company leveraging AI to develop treatments for Alzheimer's & metabolic disorders.
  • IGC-AD1 is a cannabinoid-based therapy currently in a Phase 2 trial for agitation in Alzheimer's dementia.
  • The company's pipeline includes TGR-63 for amyloid plaques & early-stage programs for neurodegeneration, tau proteins, & metabolic dysfunctions.
  • Forward-looking statements warn of risks including regulatory approval hurdles, economic conditions, & potential AI algorithm failures.